X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (88) 88
index medicus (85) 85
diabetes (81) 81
type 2 diabetes (79) 79
diabetes mellitus, type 2 - drug therapy (74) 74
hypoglycemic agents - therapeutic use (55) 55
endocrinology & metabolism (46) 46
internal medicine (46) 46
medicine & public health (45) 45
metformin (44) 44
female (42) 42
hypoglycemic agents - economics (42) 42
male (41) 41
cost-effectiveness (38) 38
sitagliptin (37) 37
glycemic control (36) 36
drug therapy (34) 34
middle aged (34) 34
cost-benefit analysis (33) 33
diabetes therapy (32) 32
pharmacology & pharmacy (32) 32
costs (31) 31
original research (29) 29
care and treatment (28) 28
diabetes mellitus, type 2 - economics (28) 28
endocrinology (28) 28
hypoglycemia (28) 28
insulin (28) 28
drug therapy, combination (27) 27
efficacy (27) 27
glucose (27) 27
type 2 diabetes mellitus (27) 27
cost analysis (26) 26
safety (26) 26
aged (25) 25
analysis (25) 25
dipeptidyl-peptidase iv inhibitors - therapeutic use (25) 25
diabetes mellitus (24) 24
liraglutide (24) 24
cardiology (23) 23
hypoglycemic agents - administration & dosage (22) 22
medicine, general & internal (22) 22
hypoglycemic agents (21) 21
research (21) 21
studies (21) 21
treatment outcome (21) 21
adult (20) 20
mortality (20) 20
patients (20) 20
dosage and administration (19) 19
medical care, cost of (19) 19
mellitus (19) 19
clinical trials (18) 18
double-blind (18) 18
pharmacology/toxicology (18) 18
dipeptidyl peptidase-4 inhibitors (17) 17
retrospective studies (17) 17
dipeptidyl peptidase-4 inhibitor (16) 16
health care sciences & services (16) 16
medicine (16) 16
risk factors (16) 16
sitagliptin phosphate (16) 16
sulfonylurea (16) 16
adherence (15) 15
diabetes mellitus, type 2 - blood (15) 15
dipeptidyl-peptidase iv inhibitors - economics (15) 15
hypoglycemic agents - adverse effects (15) 15
insulin glargine (15) 15
review (15) 15
united states (15) 15
drug dosages (14) 14
exenatide (13) 13
glycated hemoglobin a - metabolism (13) 13
hemoglobin (13) 13
metformin - therapeutic use (13) 13
add-on (12) 12
association (12) 12
blood glucose - drug effects (12) 12
health economics (12) 12
health technology assessment (12) 12
quality-adjusted life years (12) 12
systematic review (12) 12
therapy (12) 12
adamantane - analogs & derivatives (11) 11
adamantane - therapeutic use (11) 11
complications (11) 11
cost (11) 11
cost-effectiveness analysis (11) 11
drug costs (11) 11
economic aspects (11) 11
health aspects (11) 11
medicine, research & experimental (11) 11
peptides - economics (11) 11
pyrazines - therapeutic use (11) 11
randomized controlled trials as topic (11) 11
saxagliptin (11) 11
sitagliptin phosphate - therapeutic use (11) 11
triazoles - therapeutic use (11) 11
venoms - economics (11) 11
blood glucose - metabolism (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2018, Volume 20, Issue 7, pp. 1732 - 1739
Aims: TECOS, a cardiovascular safety trial (identifier: NCT00790205) involving 14 671 patients with type 2 diabetes and cardiovascular disease, demonstrated... 
costs | sitagliptin | dipeptidyl peptidase‐4 inhibitor | cost analysis | diabetes | dipeptidyl peptidase-4 inhibitor | MORTALITY | GLUCOSE | DISEASE | ENDOCRINOLOGY & METABOLISM | RISK | DEATH | MELLITUS | Hypoglycemic Agents - economics | Length of Stay - economics | United States | Humans | Middle Aged | Hospitalization - statistics & numerical data | Diabetes Mellitus, Type 2 - economics | Male | Health Resources - statistics & numerical data | Drug Costs - statistics & numerical data | Female | Equivalence Trials as Topic | Length of Stay - statistics & numerical data | Hypoglycemic Agents - therapeutic use | Proportional Hazards Models | Health Resources - economics | Linear Models | Sitagliptin Phosphate - economics | Randomized Controlled Trials as Topic | Cost-Benefit Analysis | Health Care Costs - statistics & numerical data | Sitagliptin Phosphate - therapeutic use | Aged | Ambulatory Care - economics | Ambulatory Care - statistics & numerical data | Diabetes Mellitus, Type 2 - drug therapy | Longitudinal Studies | Hospitalization - economics | Type 2 diabetes | Hypoglycemic agents | Valuation | Medical economics | Analysis | Patient outcomes | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Patients | Diabetes mellitus | Generalized linear models | Index Medicus | Clinical Medicine | costs; cost analysis; diabetes; dipeptidyl peptidase-4 inhibitor; sitagliptin | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Journal Article
BMC Health Services Research, ISSN 1472-6963, 02/2018, Volume 18, Issue 1, pp. 78 - 78
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2008, Volume 10, Issue 1, pp. 43 - 55
Objective:  Sitagliptin is a novel oral incretin enhancer that acts by inhibiting the dipeptidyl peptidase 4 enzyme and is indicated in Europe as a treatment... 
sitagliptin | type 2 diabetes | cost‐effectiveness | UKPDS | economic evaluation | discrete event simulation | economic modelling | diabetes‐related complications | Type 2 diabetes | Economic evaluation | Economic modelling | Sitagliptin | Discrete event simulation | Cost-effectiveness | Diabetes-related complications | cost-effectiveness | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | EFFICACY | SAFETY | PREVENTION | diabetes-related complications | RISK | MELLITUS | GLUCAGON-LIKE PEPTIDE-1 | DISEASE | ENDOCRINOLOGY & METABOLISM | COMPLICATIONS | Triazoles - administration & dosage | Metformin - therapeutic use | Hypoglycemic Agents - economics | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Diabetes Mellitus, Type 2 - economics | Male | Models, Economic | Thiazolidinediones - administration & dosage | Sulfonylurea Compounds - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Metformin - economics | Hypoglycemic Agents - administration & dosage | Triazoles - economics | Female | Sulfonylurea Compounds - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Pyrazines - economics | Europe | Thiazolidinediones - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Health Care Costs | Models, Biological | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Care and treatment | Analysis | Glycosylated hemoglobin | Models | Hypoglycemic agents | Diabetes | Research | Health aspects | Diabetes therapy | Medical care, Cost of | Index Medicus
Journal Article
Value in Health Regional Issues, ISSN 2212-1099, 12/2015, Volume 8, pp. 8 - 19
To assess the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico.... 
cost-effectiveness | dipeptidyl peptidase-4 inhibitor | type 2 diabetes | SGLT2 inhibitor | Type 2 diabetes | Dipeptidyl peptidase-4 inhibitor | Cost-effectiveness
Journal Article
Advances in Therapy, ISSN 0741-238X, 1/2016, Volume 33, Issue 1, pp. 68 - 81
Journal Article
Advances in Therapy, ISSN 0741-238X, 12/2014, Volume 31, Issue 12, pp. 1287 - 1305
Journal Article
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 2/2009, Volume 26, Issue 2, pp. 217 - 229
Exenatide (Byetta®, Amylin Pharmaceuticals Inc., CA, USA) and sitagliptin (Januvia®, Merck & Co, NJ, USA) are two antidiabetic agents recently approved by the... 
total medical costs | Rheumatology | Oncology | Internal Medicine | associated costs | sitagliptin | total diabetes-related medical costs | type 2 diabetes | Medicine & Public Health | Pharmacology/Toxicology | Cardiology | Endocrinology | exenatide | Type 2 diabetes | Sitagliptin | Total medical costs | Total diabetes-related medical costs | Exenatide | Associated costs | MEDICINE, RESEARCH & EXPERIMENTAL | METFORMIN | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | SULFONYLUREA | EFFICACY | INSULIN-SECRETION | HEALTH-CARE COSTS | OBESITY | EXENDIN-4 | PHARMACOLOGY & PHARMACY | WEIGHT | Multivariate Analysis | Hypoglycemic Agents - economics | United States | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Diabetes Mellitus, Type 2 - economics | Male | Pyrazines - therapeutic use | Diabetes Mellitus, Type 2 - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Health Services Research | Cost Savings | Dipeptidyl-Peptidase IV Inhibitors - economics | Peptides - economics | Drug Costs - statistics & numerical data | Triazoles - economics | Aged, 80 and over | Adult | Female | Retrospective Studies | Sitagliptin Phosphate | Pyrazines - economics | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Insurance Claim Review - statistics & numerical data | Venoms - economics | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Triazoles - pharmacology | Regression Analysis | Emergency Service, Hospital - economics | Health Care Costs - statistics & numerical data | Venoms - therapeutic use | Aged | Ambulatory Care - economics | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Peptides - therapeutic use | Hypoglycemic agents | Medical economics | Analysis | Diabetes therapy | Health technology assessment
Journal Article